Abbvie Signs ELAHERE Reimbursement LoI With The Pan-Canadian Pharmaceutical Alliance

Ovarian cancer is the leading cause of death from gynecological cancers in Canada.1 In 2026, an estimated 3,000 individuals were diagnosed. Most are diagnosed at an advanced stage, and many eventually develop platinum-resistant disease, a difficult-to-treat form of the disease that can leave women with limited treatment options.4

The burden of ovarian cancer is also a women's health equity issue. Women across Canada rely on having equitable access to meaningful advances in care, regardless of where they live. Continued collaboration across the healthcare system will be important to help translate innovation into timely access for eligible patients.

ELAHERE® represents an important innovation for this patient population. It is the first novel targeted monotherapy to demonstrate statistically significant and clinically meaningful improvements in overall survival compared to single agent chemotherapy alone for FRα-positive patients with platinum-resistant ovarian cancer.2

ELAHERE® is an antibody-drug conjugate (ADC) indicated for the treatment of folate receptor-alpha (FRα) positive, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer who have received one to three prior systemic treatment regimens.2,3

The conclusion of pCPA negotiations represents an important milestone in the reimbursement process and brings eligible women one step closer to potential access to ELAHERE® through provincial and territorial public drug plans.

Following the completion of pCPA negotiations, AbbVie looks forward to continued collaboration with provincial and territorial governments and other key stakeholders to support timely and equitable public reimbursement of ELAHERE® for individuals with FRα-positive, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer.